Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging
1 other identifier
observational
90
1 country
2
Brief Summary
Cardiac magnetic resonance imaging has emerged as a potential valuable test for the early detection of Pulmonary Arterial Hypertension. A number of reports have provided some preliminary evidence that Pulmonary Artery (PA) stiffness may be accurately detected by imaging of the pulmonary artery in order to measure PA stiffness. In addition, cardiac MRI could play provide early and effective treatment for Pulmonary Arterial Hypertension (PAH).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2011
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2011
CompletedFirst Submitted
Initial submission to the registry
October 8, 2011
CompletedFirst Posted
Study publicly available on registry
October 13, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2014
CompletedMarch 17, 2016
March 1, 2016
2.8 years
October 8, 2011
March 15, 2016
Conditions
Keywords
Eligibility Criteria
The population will consist of a total of 90 subjects separated evenly into the following subgroups: 1) Mild PAH, 2) Moderate or Severe PAH, and 3) Normal Controls.
You may qualify if:
- Consecutive patients aged ≥ 18 years with PAH as dictated by a comprehensive examination and echocardiography will be included for enrollment.
You may not qualify if:
- Age \< 18 years
- Pregnancy
- Mechanical ventilation
- Acute or chronic renal failure (creatinine clearance \< 30 ml/min or requiring renal replacement therapy)
- Inability to perform MRI (i.e. claustrophobia, severe obesity (\> 150 kg), device incompatible with MRI)
- Significant arrhythmia that precludes adequate ECG-gating for the MRI (i.e. atrial fibrillation with highly variable cycle lengths)
- Prior heart or lung transplantation
- Left ventricular systolic (ejection fraction \< 50%) or diastolic failure (based on Framingham criteria for heart failure with preserved ejection fraction)
- Significant left-sided valvular disease (≥ moderate aortic stenosis, mitral stenosis, aortic regurgitation, mitral regurgitation) or prior valve surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
Study Sites (2)
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
Mayo Clinic
Jacksonville, Florida, 32224, United States
Related Publications (1)
Ray JC, Burger C, Mergo P, Safford R, Blackshear J, Austin C, Fairweather D, Heckman MG, Zeiger T, Dubin M, Shapiro B. Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension. Int J Cardiovasc Imaging. 2019 Oct;35(10):1881-1892. doi: 10.1007/s10554-018-1397-y. Epub 2018 Jun 22.
PMID: 29934885DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Brian Shapiro, M.D.
Mayo Clinic
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 8, 2011
First Posted
October 13, 2011
Study Start
August 1, 2011
Primary Completion
June 1, 2014
Study Completion
June 1, 2014
Last Updated
March 17, 2016
Record last verified: 2016-03